Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Biol Macromol ; 77: 330-5, 2015.
Article in English | MEDLINE | ID: mdl-25841377

ABSTRACT

Antifungal activity against the dermatophytic fungus Trichophyton rubrum by a well-characterized chitooligosaccharides (COS) sample, hydrolyzed using a recombinant chitosanase, was investigated in vitro and in vivo. The minimum inhibitory concentration (MIC) of COS ranged between 0.25 and 0.50%, which was measured using a microdilution method. Analysis of inhibition rates using an agar diffusion method showed that treatment with 0.5% and 1% COS significantly suppressed T. rubrum cell growth (p<0.05 and p<0.01, respectively, in comparison with untreated control). Morphological changes and structural alterations of cells were observed by TEM. In vivo efficacy of COS in treatment of T. rubrum dermatophytosis was evaluated using a guinea pig model. Skin lesion scores revealed a strong, dose-dependent therapeutic effect of COS. The 5% COS group showed a reduction of skin lesions even greater than that of the positive control group treated with 1% fluconazole (FCZ). Histological analysis revealed no inflammation or tissue destruction in the groups treated with 5% COS or 1% FCZ. Hyperkeratosis was also observed, perhaps resulting from a defensive response of the tissue cells to COS. The findings indicate that COS has excellent potential for development of novel antifungal drugs for clinical treatment/remission of dermatophytoses.


Subject(s)
Antifungal Agents/pharmacology , Chitin/analogs & derivatives , Trichophyton/drug effects , Animals , Antifungal Agents/therapeutic use , Chitin/pharmacology , Chitin/therapeutic use , Chitosan , Guinea Pigs , Microbial Sensitivity Tests , Oligosaccharides , Tinea/drug therapy , Trichophyton/physiology
2.
Planta Med ; 80(13): 1107-12, 2014 Aug.
Article in English | MEDLINE | ID: mdl-25127022

ABSTRACT

A novel heteroglycan, Cordyceps sinensis polysaccharide 1 (molecular weight 1 17 × 10(5) Da), was isolated and purified from mycelia of the fungus C. sinensis obtained by solid-state culture. Structural characterization by chemical analysis, GC-MS, FTIR, and NMR spectroscopy showed that C. sinensis polysaccharide 1 was mainly composed of (1 → 6)-linked α-D-Glc and α-D-Gal, with minor ß-(1 → 4)-D-Xyl and ß-(1 → 4)-D-Man residues probably located in the side chains with a trace amount of α-(1 → 3)-L-Rha residue. In biological assays, C. sinensis polysaccharide 1 significantly inhibited proliferation of sarcoma 180 cells and induced apoptosis in a dose-dependent manner. Further studies will elucidate the antitumor mechanism of C. sinensis polysaccharide 1 and promote its utilization for the development of novel, effective anticancer drugs.


Subject(s)
Antineoplastic Agents/pharmacology , Cordyceps/chemistry , Polysaccharides/pharmacology , Animals , Antineoplastic Agents/chemistry , Antineoplastic Agents/isolation & purification , Apoptosis/drug effects , Carcinoma, Non-Small-Cell Lung/drug therapy , Carcinoma, Non-Small-Cell Lung/pathology , Cell Proliferation/drug effects , Gas Chromatography-Mass Spectrometry , Magnetic Resonance Spectroscopy , Mycelium/chemistry , Polysaccharides/chemistry , Polysaccharides/isolation & purification , Sarcoma 180/drug therapy , Sarcoma 180/pathology , Spectroscopy, Fourier Transform Infrared
3.
Int J Biol Macromol ; 62: 330-5, 2013 Nov.
Article in English | MEDLINE | ID: mdl-24080320

ABSTRACT

Chitooligosaccharides (COS) display a variety of important biological activities, including antimicrobial, antitumor, anti-inflammatory, and immunoenhancing. In the present study, a COS sample (degree of polymerization 4-11, analyzed by FTIR and MALDI-TOF-MS) prepared by hydrolysis with a recombinant chitosanase was orally administered to mice for evaluation of its effect on cyclophosphamide (Cy)-induced immunosuppression. Thymus and spleen indices, delayed-type hypersensitivity (DTH) reaction, macrophage phagocytosis, and certain enzyme activities were significantly higher in mice treated with COS+Cy than in mice treated with Cy alone. ELISA experiments showed that COS treatment enhanced production of the cytokines IL-2, IL-12, and IFN-γ but decreased production of IL-10 in sera of Cy-treated mice. The well-defined COS product studied displayed strong immunoenhancing activity and a protective effect against Cy-induced immunosuppression. COS-derived products should be further investigated for possible immunostimulatory applications in the food and pharmaceutical industries.


Subject(s)
Chitosan/chemistry , Cyclophosphamide/adverse effects , Immune Tolerance/drug effects , Oligosaccharides/chemistry , Oligosaccharides/pharmacology , Acid Phosphatase/metabolism , Animals , Cytokines/metabolism , Hypersensitivity, Delayed/immunology , L-Lactate Dehydrogenase/metabolism , Macrophages/drug effects , Macrophages/immunology , Male , Mice , Phagocytosis/drug effects , Spleen/drug effects , Spleen/enzymology , Spleen/immunology , Thymus Gland/drug effects , Thymus Gland/immunology
SELECTION OF CITATIONS
SEARCH DETAIL